Ircon International Limited (BOM:541956)
India · Delayed Price · Currency is INR 167.70
-4.10 (-2.39%)
At close: Aug 7, 2025
Inozyme Pharma Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Net Income | - | 7,274 | 9,296 | 7,652 | 5,923 | 3,911 | Upgrade |
Depreciation & Amortization | - | 1,179 | 972 | 1,062 | 941.9 | 919.3 | Upgrade |
Other Amortization | - | - | 32.3 | 8.5 | 2.3 | 1.6 | Upgrade |
Loss (Gain) From Sale of Assets | - | -0.4 | -3.3 | -24.4 | -9.9 | -37.5 | Upgrade |
Asset Writedown & Restructuring Costs | - | - | - | 4.2 | 7.5 | - | Upgrade |
Loss (Gain) From Sale of Investments | - | -502.6 | -303.5 | -3.2 | 39.6 | -20.1 | Upgrade |
Loss (Gain) on Equity Investments | - | -597.7 | -462.2 | -314.4 | -599.4 | -318.6 | Upgrade |
Other Operating Activities | - | -3,060 | -50.2 | -1,576 | 320 | 756.6 | Upgrade |
Change in Accounts Receivable | - | -5,249 | 605 | -1,686 | -644.3 | -795.8 | Upgrade |
Change in Inventory | - | -431.1 | -484.7 | 705.3 | -1,559 | 2,000 | Upgrade |
Change in Accounts Payable | - | 3,632 | 320.2 | -1,718 | 2,692 | 1,688 | Upgrade |
Change in Other Net Operating Assets | - | -13,339 | -10,707 | -6,889 | 7,027 | -2,924 | Upgrade |
Operating Cash Flow | - | -11,095 | -785.5 | -2,779 | 14,141 | 5,181 | Upgrade |
Operating Cash Flow Growth | - | - | - | - | 172.92% | - | Upgrade |
Capital Expenditures | - | -10,484 | -8,446 | -647.9 | -197.7 | -45.3 | Upgrade |
Sale of Property, Plant & Equipment | - | 9.8 | 400.7 | 20.5 | 6 | 206.6 | Upgrade |
Cash Acquisitions | - | -639.6 | - | - | - | - | Upgrade |
Sale (Purchase) of Intangibles | - | -37.1 | -37.1 | -349.7 | -211.1 | -0.3 | Upgrade |
Sale (Purchase) of Real Estate | - | -112.8 | -25.8 | -95.4 | -0.7 | -304.9 | Upgrade |
Investment in Securities | - | 3,283 | -4,968 | -1,159 | -1,054 | -299.9 | Upgrade |
Other Investing Activities | - | 8,300 | 6,021 | 18,011 | -10,816 | -7,330 | Upgrade |
Investing Cash Flow | - | 319.2 | -7,055 | 15,780 | -12,274 | -7,774 | Upgrade |
Long-Term Debt Issued | - | 21,560 | 11,321 | 1,653 | 11,241 | 3,309 | Upgrade |
Long-Term Debt Repaid | - | -4,607 | -699.6 | -601.3 | -559.9 | -0.2 | Upgrade |
Net Debt Issued (Repaid) | - | 16,953 | 10,621 | 1,052 | 10,681 | 3,309 | Upgrade |
Common Dividends Paid | - | -2,775 | -2,822 | -2,304 | -3,339 | -1,580 | Upgrade |
Other Financing Activities | - | -2,618 | -1,399 | -982 | -634.3 | -43.5 | Upgrade |
Financing Cash Flow | - | 11,560 | 6,401 | -2,234 | 6,708 | 1,686 | Upgrade |
Foreign Exchange Rate Adjustments | - | 216.5 | -143.9 | 37.4 | -138.9 | -79.7 | Upgrade |
Net Cash Flow | - | 1,001 | -1,583 | 10,803 | 8,436 | -986.7 | Upgrade |
Free Cash Flow | - | -21,579 | -9,231 | -3,427 | 13,943 | 5,136 | Upgrade |
Free Cash Flow Growth | - | - | - | - | 171.48% | - | Upgrade |
Free Cash Flow Margin | - | -20.06% | -7.49% | -3.31% | 18.89% | 9.60% | Upgrade |
Free Cash Flow Per Share | - | -22.93 | -9.81 | -3.64 | 14.82 | 5.46 | Upgrade |
Cash Interest Paid | - | 2,618 | 1,615 | 1,102 | 646.3 | 43.5 | Upgrade |
Cash Income Tax Paid | - | 3,067 | 866.4 | 740 | 326.2 | 425.2 | Upgrade |
Levered Free Cash Flow | - | -3,647 | -10,473 | -8,796 | 39,195 | -20,107 | Upgrade |
Unlevered Free Cash Flow | - | -2,277 | -9,572 | -8,098 | 39,535 | -20,028 | Upgrade |
Change in Working Capital | - | -15,387 | -10,266 | -9,588 | 7,515 | -30.7 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.